Combined blood markers correctly detect early pancreatic cancer in human cancer cells
A newly identified biomarker panel could pave the way to earlier detection and better treatment for pancreatic cancer, according to new research from the Perelman School of Medicine at University of Pennsylvania. Currently over 53,000 people in the United States are diagnosed with pancreatic cancer — the fourth leading cause of cancer death — every year. The blood biomarkers, detailed today in Science Translational Medicine, correctly detected pancreatic cancer in blood samples from patients at different stages of their disease.
The majority of pancreatic cancer patients are not diagnosed until an advanced stage, beyond the point at which their tumors can be surgically removed.
A team led by Ken Zaret, PhD, director of the Penn Institute for Regenerative Medicine and the Joseph Leidy Professor of Cell and Developmental Biology, and Gloria Petersen, PhD, from the Mayo Clinic, identified a pair of biomarkers that physicians could soon use to discover the disease earlier.
“Starting with our cell model that mimics human pancreatic cancer progression, we identified released proteins, then tested and validated a subset of these proteins as potential plasma biomarkers of this cancer,” Zaret said. The authors anticipate that health care providers will use the early-detection biomarkers to test for their presence and levels in blood from pancreatic cancer patients and blood drawn from individuals with a high risk of developing pancreatic cancer, including those who have a first-degree relative with pancreatic cancer, are genetically predisposed to the disease, or who had a sudden onset of diabetes after the age of 50.
“Early detection of cancer has had a critical influence on lessening the impact of many types of cancer, including breast, colon, and cervical cancer. A long standing concern has been that patients with pancreatic cancer are often not diagnosed until it is too late for the best chance at effective treatment,” said Robert Vonderheide, MD, DPhil, director of the Abramson Cancer Center (ACC) at the University of Pennsylvania. “Having a biomarker test for this disease could dramatically alter the outlook for these patients.”
Novel method for discovering pancreatic cancer biomarkers
Credit: The lab of Ken Zaret, Perelman School of Medicine, University of Pennsylvania
The biomarker panel, enabled by discovery work of first author Jungsun Kim, PhD, a postdoctoral fellow in Zaret’s lab, builds on a first-of-its-kind human-cell model of pancreatic cancer progression the lab described in 2013. They used stem-cell technology to create a cell line from a patient with advanced pancreatic ductal adenocarcinoma. Genetically reprogramming late-stage human cancer cells to a stem-cell state enabled them to force the reprogrammed cells to progress to an early cancerous state, revealing secreted blood biomarkers of early-stage disease along the way.
The best candidate biomarker, plasma thrombospondin-2 (THBS2), was screened against 746 cancer and control plasma samples using an inexpensive, commercially available protein-detection assay. The team found that blood levels of THBS2, combined with levels of a known later-stage biomarker called CA19-9, was reliable at detecting the presence of pancreatic cancer in patients.
The team refined the assay with independent investigations of plasma samples from patients with different stages of cancer, from individuals with benign pancreatic disease, and from healthy controls, all obtained from Petersen, who directs the biospecimen resource program for pancreas research at the Mayo Clinic.
“Positive results for THBS2 or CA19-9 concentrations in the blood consistently and correctly identified all stages of the cancer,” Zaret said. “Notably, THBS2 concentrations combined with CA19-9 identified early stages better than any other known method.” The combination panel also improved the ability to distinguish cases of cancer from pancreatitis. The panel will next be validated in a set of samples from pancreatic cancer patients who provided a research blood sample prior to their diagnosis.
The Latest on: Pancreatic cancer
Postmenopausal calcium channel blocker use tied to pancreatic cancer risk
on April 18, 2018 at 11:03 am
Researchers reviewed data for 145,551 postmenopausal women aged 50 to 79 years enrolled in the Women's Health Initiative from 1993 to 1998 and found that those who had ever used short-acting calcium channel blockers had a 66% greater risk of pancreatic ... […]
Blood pressure meds linked to higher pancreatic cancer risk in postmenopausal women
on April 18, 2018 at 9:38 am
A class of blood pressure medications—short-acting calcium channel blockers (CCBs)—was associated with an increased risk of pancreatic cancer in postmenopausal women, according to a study presented April 17 at the American Association for Cancer ... […]
Specific Type Of Blood Pressure Drug Increases Risk Of Pancreatic Cancer In Postmenopausal Women
on April 18, 2018 at 7:25 am
18 April 2018, 9:57 am EDT By Rubi Valdez Tech Times Sign up for our email newsletter today. Tech Times' biggest stories, delivered to your inbox. […]
Calcium Channel Blockers May Up Pancreatic Cancer Risk in Women
on April 18, 2018 at 7:19 am
HealthDay News — Use of short-acting calcium channel blockers (CCBs) is associated with increased risk of pancreatic cancer in postmenopausal women, according to a study presented at the annual meeting of the American Association for Cancer Research ... […]
MabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual Meeting
on April 18, 2018 at 6:11 am
Dr. Maffuid's presentation summarized results from the first cohort of three patients treated in the Phase 1 clinical trial of the Company's MVT-1075 radiopharmaceutical product in late stage pancreatic cancer. These results at the initial dose support a ... […]
Attention women: Your choice of blood pressure medicine may affect your risk of pancreatic cancer
on April 18, 2018 at 2:10 am
In findings with potentially broad implications for the public's health, new research has found that some women who treat their high blood pressure with a class of drugs that relaxes the blood vessels were more likely to develop pancreatic cancer than ... […]
Some blood pressure meds tied to pancreatic cancer risk in women
on April 17, 2018 at 6:26 pm
TUESDAY, April 17, 2018 -- Certain drugs prescribed to treat high blood pressure may boost a woman's risk for developing pancreatic cancer after menopause, new research suggests. In a large study of postmenopausal women, those who had ever taken a short ... […]
Global ROS1 initiative: A patient-researcher collaboration targeting ROS1 cancer
on April 17, 2018 at 9:01 am
While "ROS1 fusion" has primarily been studied in lung cancer, the Global ROS1 Initiative includes ROS1-positive (ROS1+) patients with melanoma and pancreatic cancer as well. And in addition to offering information and support, the group is helping to ... […]
Short-acting calcium channel blockers were associated with increased risk of pancreatic cancer in postmenopausal women
on April 17, 2018 at 7:17 am
Calcium channel blockers (CCBs), specifically the short-acting form of CCBs, which are prescribed to treat high blood pressure, were associated with an increased risk of pancreatic cancer in postmenopausal women, according to a study presented at the AACR ... […]
Cancer risk found to be three times greater after acute thrombosis in the leg
on April 16, 2018 at 6:30 pm
"It is especially, but not only, the smoking-related forms of cancer that show up after the arterial thrombosis. The risk is highest for lung and pancreatic cancer, both of which are related to smoking. However, other forms of cancer such as colon cancer ... […]
via Google News and Bing News